Tuesday, Jun 4, 2024 · SEC filings
What the smart money revealed on Jun 4
1,332 insider filings came in. We hid 130 planned (10b5-1) sellers and 1,025 people whose filings were routine, like grants and tax withholding.
Inhibrx Biosciences (INBX) Director Jon Kayyem bought $4.93M
286,786 shares on the open market. Not a grant or an option exercise.
Norfolk Southern (NSC) Director Sameh Fahmy bought $444K
2,000 shares on the open market. Not a grant or an option exercise. Their past buys: 4 of 4 checked quarters beat the typical stock 6 months later.
SLM Director Richard Blackley bought $249K
11,702 shares on the open market. Not a grant or an option exercise.
Capital Southwest (CSWC) Director William Thomas III bought $243K
9,400 shares on the open market. Not a grant or an option exercise.
Agilysys (AGYS) President and CEO Ramesh Srinivasan sold $9.35M
Not marked as a planned 10b5-1 sale. Sold 11% of the shares they held directly. Still holds 838,367 shares.
Humacyte (HUMA) President Laura Niklason sold $7.83M
Not marked as a planned 10b5-1 sale. Sold 16% of the shares they held directly. Still holds 5.19M shares.
Abercrombie & Fitch (ANF) Director Sarah Gallagher sold $479K
Not marked as a planned 10b5-1 sale. Sold every share held directly.
Show 39 more real buys
Show 105 more real sales
13F season
Holdings as of Mar 31, 2024 were due May 15
50 funds have filed. 49 filed for the quarter before.
Biggest real insider buys, May 29–Jun 4
Open-market buys by officers and directors, filed in the 7 days up to Jun 4.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.